Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of one of the following:
• * Acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL) in first early relapse, second remission, or subsequent remission
• * AML in first complete remission with one of the following adverse features:
• * Antecedent hematologic disorder such as myelodysplasia
• * AML resulting from prior chemotherapy or radiotherapy
• * More than 1 course of induction chemotherapy to achieve remission or adverse cytogenetics such as Philadelphia chromosome 9:22, +8, +11; abnormal 12p; or deletions of chromosomes 5, 7, or 20 (3:3)
• * ALL in first complete remission with poor risk cytogenetics such as
• * Philadelphia chromosome 9:22, 8:14, or 4:11 OR
• * WBC greater than 100,000/mm3 OR
• * Time to achieve complete remission more than 4 weeks
• * Chronic myelogenous leukemia in chronic or accelerated phase
• * Myelodysplastic syndromes
• * Refractory anemia with excess blasts (RAEB) OR
• * RAEB in transformation
• Unrelated bone marrow donor available
• * If matched at 6 of 6 HLA-A, -B, and -DR loci, patient must be 12 to 50 years
• * If matched at 5 of 6 loci, patient must be 12 to 35 years
• No matched sibling donor available
• No uncontrolled CNS leukemia
• PATIENT CHARACTERISTICS:
• Age:
• See Disease Characteristics
• 12 to 50
• Performance status:
• Karnofsky 70-100%
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• See Disease Characteristics
• Hepatic:
• Bilirubin less than 2.5 times upper limit of normal (ULN)
• SGOT or SGPT less than 2.5 times ULN
• Renal:
• Creatinine no greater than 1.5 mg/dL
• Cardiovascular:
• LVEF greater than 50% without medication
• Pulmonary:
• DLCO and FVC at least 50% predicted
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other serious medical illness
• No uncontrolled diabetes mellitus
• No uncontrolled and/or active infection
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 3 weeks since prior immunotherapy and recovered
• At least 1 year since prior autologous transplantation
• No prior allogeneic transplantation
• Chemotherapy:
• See Disease Characteristics
• At least 3 weeks since prior chemotherapy (except hydroxyurea) and recovered
• Endocrine therapy:
• At least 3 weeks since prior hormonal therapy and recovered
• Radiotherapy:
• See Disease Characteristics
• At least 3 weeks since prior radiotherapy and recovered
• No prior radiotherapy at doses that would preclude study
• Surgery:
• Not specified